Chéret, A., Nembot, G., Mélard, A., Lascoux, C., Slama, L., Miailhes, P., Yeni, P., Abel, S., Avettand-Fenoel, V., Venet, A., Chaix, M., Molina, J., Katlama, C., Goujard, C., Tamalet, C., Raffi, F., Lafeuillade, A., Reynes, J., Ravaux, I., Hoën, B., Delfraissy, J., Meyer, L., Rouzioux, C., & , (n.d.). intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial. Lancet infectious diseases, 15(4), 387–396. http://access.bl.uk/ark:/81055/vdc_100051426994.0x00001c